Drug intelligence / Profile preview

Ad-HBx-mIL-12

Development stage: Preclinical
Lead developer: Sichuan University
Modality: Gene Therapies
Administration: Intratumoral

Overview

**Ad-HBx-mIL-12** is an experimental recombinant adenoviral gene-therapy vector engineered to express hepatitis B virus X protein and mouse interleukin-12. It was developed in preclinical hepatocellular carcinoma models to combine HBx-associated tumor-cell apoptosis and anti-angiogenic activity with IL-12-driven antitumor immune activation. Local tumor treatment produced tumor-growth suppression, increased intratumoral CD8-positive T cells, macrophages, and dendritic cells, and reduced tumor angiogenesis in vivo. ([spandidos-publications.com](https://www.spandidos-publications.com/ijmm/30/3/599))

Other names: HBx-mIL-12HBx-mIL12HBx-mIL 12

Targets

IL-12R (Interleukin-12 receptor)HBx (Hepatitis B virus X protein)

Beyond the preview

Go deeper on Ad-HBx-mIL-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad-HBx-mIL-12.

Explore the full profile